|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
X
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
Arthralgia |
|
hypertonia |
|
myalgia |
|
spinal hyperostosis |
|
headache |
|
nausea |
|
vomiting |
|
Ophthalmologic effects, including blepharitis |
|
conjunctivitis |
|
eye irritation |
|
photophobia |
|
other visual problems |
|
paronychia |
|
Dermatologic effects, such as abnormal skin odor |
|
dermatitis |
|
psoriasiform rash |
|
fissuring |
|
hypertrophy |
|
infection |
|
ulceration of skin |
|
otitis externa |
|
paresthesia |
|
pyogenic granuloma |
|
purpura |
|
hepatitis |
|
jaundice |
|
pancreatitis |
|
influenza-like symptoms |
|
laryngitis |
|
pharyngitis |
|
ophthalmologic effects, such as cortical, nuclear, and posterior subcapsular cataracts, pannus, or subepithelial corneal lesions |
|
decreased night vision |
|
pseudotumor cerebri |
|
recurring stye |
|
vulvovaginitis |
|
Alopecia |
|
dermatologic effects, such as ceruminosis |
|
chapped lips or cheilitis |
|
dry, irritated mucous membranes of nose or rhinitis |
|
pruritus |
|
scaling and peeling of eyelids, fingertips, palms, or soles of feet |
|
sticky skin |
|
difficulty in wearing contact lenses |
|
gingivitis or stomatitis |
|
photosensitivity |
|
xerophthalmia |
|
unusual thirst |
|
Constipation |
|
diarrhea |
|
fatigue |
|
increased sweating |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Diabetes mellitus, type 1 |
|
Pancreatitis |
|
>> Hepatic disease, severe |
|
>> Renal disease, severe |
|
|
ADULT DOSE:
|
|
Antipsoriatic (systemic)-Initial: Oral, 25 or 50 mg a day (or 0.5 mg per kg of body weight a day) as a single dose; dose may be increased up to 75 mg a day after four weeks, if needed and tolerated .
Maintenance: Oral, 25 to 50 mg a day, increased if needed to 75 mg a day .
Note: Lower doses of acitretin are used when initiating combination therapy in the treatment of severe plaque psoriasis .
[Keratinization stabilizer (systemic)]-Initial: Oral, 25 mg a day; dose may be increased up to 75 mg a day after four weeks, if needed and tolerated .
Maintenance: Oral, 10 to 50 mg a day . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Antipsoriatic-Safety and efficacy have not been established.
[Keratinization stabilizer (systemic)]-Initial: Oral, 0.5 mg per kg of body weight once a day. May be increased to 1 mg per kg a day for limited periods of time as needed, not to exceed a total dose of 35 mg a day.
Maintenance: Oral, 20 mg or lower once a day for prolonged treatment. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
Oral, 35 mg a day.
|
|
ELDERLY DOSE:
|
|
Antipsoriatic (systemic)-Initial: Oral, 25 or 50 mg a day (or 0.5 mg per kg of body weight a day) as a single dose; dose may be increased up to 75 mg a day after four weeks, if needed and tolerated .
Maintenance: Oral, 25 to 50 mg a day, increased if needed to 75 mg a day .
Note: Lower doses of acitretin are used when initiating combination therapy in the treatment of severe plaque psoriasis .
[Keratinization stabilizer (systemic)]-Initial: Oral, 25 mg a day; dose may be increased up to 75 mg a day after four weeks, if needed and tolerated .
Maintenance: Oral, 10 to 50 mg a day . |
|
|
|
|
|